Overview

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Status:
Completed

Trial end date:
2017-08-22

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Ipilimumab
Paclitaxel